

FluoroPharma Presents at the Cavendish Global Health Impact Forum

FluoroPharma President, Thomas Tulip, presented at the Cavendish Global Health Impact Forum, co-hosted by Cleveland Clinic in Cleveland, Ohio on October 27th, 2015.

"I was delighted to participate in and present at the Cavendish Global event, held in conjunction with the Cleveland Clinic Innovation Summit. We very much appreciate this great opportunity to share our vision for the company and describe our aspirations to improve outcomes for patients with devastating cardiovascular disease, in a setting designed to bring together like-minded professionals who want to make a difference in the world through directed philanthropy and advanced medical technologies."

The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading family offices, accomplished foundations, research institutions, and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of family offices, Cavendish Impact Forums are hosted by leading institutions around the world and takes place three times each year. The current Forum was co-hosted by The Cleveland Clinic and Cleveland Clinic Innovations.

About FluoroPharma Medical

FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The company has licensed technology from the Massachusetts General Hospital in Boston.

The company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.

FluoroPharma's initial focus is the development of breakthrough PET imaging agents and is advancing two products in clinical trials for assessment of acute and chronic forms of coronary artery disease. These novel agents have been designed to rapidly target myocardial cells.

In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia and Mexico.

About Cavendish Global

Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; the next Forum is being co-hosted by The Cleveland Clinic and Cleveland Clinic Innovations. For more information: <http://cavendishglobal.com>

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking.

Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding FluoroPharma's research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma's filings with the United States Securities and Exchange Commission. FluoroPharma undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: FluoroPharma Medical, Inc.